In vitro sensitivity of B-cell chronic lymphocytic leukemia to cladribine and its combinations with mafosfamide and/or mitoxantrone

Oncology Reports

Volumn 16, Issue 6, 2006, Pages 1389-1395

  Kobylinska, Agnieszka ^a,d   Bednarek, Jolanta ^a   Blonski, Jerzy Z ^b   Hanausek, Malgorzata ^c   Walaszek, Zbigniew ^c   Robak, Tadeusz ^b   Kilianska, Zofia M ^a  

^a UNIVERSITY OF LODZ   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c Mays Cancer Center at UT Health San Antonio   (United States)

^d NOFER INSTITUTE OF OCCUPATIONAL MEDICINE   (Poland)

Author keywords

Apoptosis related events; B cell chronic lymphocytic leukemia; Chemosensitivity; In vitro

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; CLADRIBINE; CYCLOPHOSPHAMIDE; DNA FRAGMENT; DRUG DERIVATIVE; LAMIN B; MAFOSFAMIDE; MITOXANTRONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PARP1 PROTEIN, HUMAN; PROTEIN BAX; PROTEIN BCL 2;

ARTICLE; B CELL LEUKEMIA; CELL CULTURE; DRUG EFFECT; FEMALE; HUMAN; IN VITRO STUDY; MALE; MITOCHONDRION; PATHOLOGY; PROTEIN TRANSPORT; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CASPASES; CLADRIBINE; CYCLOPHOSPHAMIDE; DNA FRAGMENTATION; FEMALE; HUMANS; LAMIN TYPE B; LEUKEMIA, B-CELL, CHRONIC; MALE; MITOCHONDRIA; MITOXANTRONE; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED;

EID: 39049189036     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.16.6.1389     Document Type: Article

References (55)

1. Gale RP, Caligaris-Cappio F, Dighiero G, Keating M, Montserrat E and Rai K: Recent progress in chronic lymphocytic leukemia. International Workshop on Chronic Lymphocytic Leukemia. Leukemia 8: 1610-1614, 1994.
2. Caligaris-Cappio F: Role of the microenvironment in chronic lymphocytic leukaemia. Br J Haematol 123: 380-388, 2003.
3. Defrance T, Casamayor-Palleja M and Krammer PH: The life and death of a B cell. Adv Cancer Res 86: 195-225, 2002.
4. Rai KR: Cladribine for the treatment of hairy cell leukemia and chronic lymphocytic leukemia. Semin Oncol 25 (Suppl 7): 19-22, 1998.
5. Rai KR, Peterson BL, Appelbaum FR, et al: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343: 1750-1757, 2000.
6. Nabhan C, Gartenhaus RB and Tallman MS: Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era. Leuk Res 28: 429-442, 2004. (Pubitemid 38453053)
7. Keating MJ: Chronic lymphocytic leukemia. Semin Oncol 26: 107-114, 1999.
8. Gandhi V and Plunkett W: Combination strategies for purine nucleoside analogs. In: Chronic Lymphoid Leukemias. Cheson BD (ed). Marcel Dekker, Inc., Basel, New York, pp195-208, 2001.
9. Robak T: Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies. Transfus Apher Sci 32: 33-44, 2005.
10. Robertson LE, Chubb S, Meyn RE, Story M, Ford R, Hittelman WN and Plunkett W: Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine. Blood 81: 143-150, 1993. (Pubitemid 23013688)
11. Van den Neste E, Cardoen S, Offner F and Bontemps F: Old and new insights into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: fludarabine and cladribine. Int J Oncol 27: 1113-1124, 2005.
12. McConkey DJ, Chandra J, Wright S, Plunkett W, McDonnell TJ, Reed JC and Keating M: Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX. J Immunol 156: 2624-2630, 1996. (Pubitemid 26091593)
13. Bellosillo B, Villamor N, Colomer D, Pons G, Montserrat E and Gil J: In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood 94: 2836-2843, 1999. (Pubitemid 29477312)
14. Chow KU, Rummel MJ, Weidmann E, et al: Induction of apoptosis by 2-chloro-2′-deoxyadenosine (2-CdA) alone and in combination with other cytotoxic drugs: synergistic effects on normal and neoplastic lymphocytes by addition of doxorubicin and mitoxantrone. Leuk Lymph 36: 559-567, 2000. (Pubitemid 30103181)
15. Robak T, Blonski JZ, Kasznicki M, et al: Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 96: 2723-2729, 2000.
16. Robak T, Blonski JZ, Kasznicki M, et al: Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in B-cell chronic lymphocytic leukemia. Leukemia 15: 1510-1516, 2001. (Pubitemid 32994668)
17. Kobylinska A, Blonski JZ, Hanausek M, et al: Determination of the in vivo effects of cladribine alone and its combination with cyclophosphamide or cyclophosphamide and mitoxantrone on Bax and Bcl-2 protein expression in B-CLL cells. Oncol Rep 11: 699-705, 2004.
18. Robak T, Blonski JZ, Gora-Tybor J, et al: Cladribine alone and in combination with cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood 108: 473-479, 2006 (Epub March 21, 2006).
19. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S and Rai KR: National Cancer Institute - sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87: 4990-4997, 1996. (Pubitemid 26189840)
20. Castejon R, Vargas JA, Briz M, Berrocal E, Gea-Banacloche JC, Romero Y, Fernandez MN and Durantez A: Induction of apoptosis by 2-chlorodeoxyadenosine in B cell chronic lymphocytic leukemia. Leukemia 11: 1253-1257, 1997. (Pubitemid 27387301)
21. Cole SPC: Rapid chemosensitivity testing of human lung tumor cells using the MTT assay. Cancer Chemother Pharmacol 17: 259-263, 1986.
22. Lowry OH, Rosebrough NJ and Farr AL: Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275, 1951.
23. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685, 1970.
24. Towbin H, Staechlin T and Gordon J: Electrophoretic transfer of protein from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 76: 4350-4354, 1979. (Pubitemid 9256559)
25. Leary JJ, Brigati JJ and Ward DC: Rapid biotin labelled DNA probes hybrized to DNA or RNA immobilized on nitrocellulose: Bio-blots. Proc Natl Acad Sci USA 80: 4045-4049, 1983.
26. Prokop A, Wieder T, Sturm I, et al: Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontanous caspase-3 processing in vivo. Leukemia 14: 1606-1613, 2000.
27. Bellosillo B, Pique M, Barragan M, et al: Aspirin and salicytate induce apoptosis and activation of caspases in B-cell chronic lymphocytic leukemia cells. Blood 92: 1406-1414, 1998. (Pubitemid 28369055)
28. Ganju N and Eastman A: Zinc inhibits Bax and Bak activation and cytochrome c release induced by chemical inducers of apoptosis but not by death-receptor-initiated pathways. Cell Death Differ 10: 652-661, 2003. (Pubitemid 36675727)
29. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES and Wang X: Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91: 479-489, 1997. (Pubitemid 27508237)
30. Degterev A, Boyce M and Yuan J: A decade of caspases. Oncogene 22: 8543-8567, 2003. (Pubitemid 38028527)
31. Hill MM, Adrian C and Martin SJ: Portrait of a killer: the mitochondrial apoptosome emerges from the shadows. Mol Interv 3: 19-26, 2003.
32. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG and Earnshaw WC: Cleavage of poly(ADP-ribose)polymerase by a proteinase with properties like ICE. Nature 371: 346-347, 1994. (Pubitemid 24300618)
33. Slee EA, Adrain C and Martin SJ: Executioner caspase-3, -6, and -7 perform distinct, non-redundant roles during the demolition phase of apoptosis. J Biol Chem 276: 7320-7326, 2001.
34. Kivinen K, Kallajoki M and Taimen P: Caspase-3 is required in the apoptotic disintegration of the nuclear matrix. Exp Cell Res 311: 62-73, 2005. (Pubitemid 41527175)
35. Cory S, Huang DC and Adams JM: The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 22: 8590-8607, 2003. (Pubitemid 38028528)
36. Hengartner MO: The biochemistry of apoptosis. Nature 407: 770-776, 2000.
37. Borner C: The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol Immunol 39: 615-647, 2003.
38. Schinzel A, Kaufmann T and Borner C: Bcl-2 family members: intracellular targeting, membrane-insertion, and changes in subcellular localization. Biochim Biophys Acta 1644: 95-105, 2004. (Pubitemid 38281266)
39. Kitada S, Andersen J, Akar S, et al: Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 91: 3379-3389, 1998. (Pubitemid 28193890)
40. Lowe SM and Lin AW: Apoptosis in cancer. Carcinogenesis 21: 485-495, 2000.
41. Ringhausen I, Schneller F, Bogner C, et al: Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL association with protein kinase Cδ. Blood 100: 3741-3748, 2002. (Pubitemid 35303946)
42. Cummings J, Ward TH, Ranson M and Dive C: Apoptosis pathway-targeted drugs from the bench to the clinic. Biochim Biophys Acta 1705: 53-66, 2004. (Pubitemid 39610420)
43. Robertson JD, Orrenius S and Zhivotovsky B: Nuclear events in apoptosis. J Struct Biol 129: 346-358, 2000.
44. Tewari M, Quan LT, O'Rourke K, et al: Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81: 801-809, 1995.
45. Chang YH and Yang H: Proteases for cell suicide: functions and regulation of caspases. Microbiol Mol Biol Rev 64: 821-846, 2000.
46. Dynlacht JR, Roberts ZV, Earles M, Henthorn J and Seno JD: Different patterns of DNA fragmentation and degradation of nuclear matrix proteins during apoptosis induced by radiation, hyperthermia or etoposide. Radiat Res 154: 515-530, 2000.
47. Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A and Nagata S: A caspase-activated DNase that degrades DNA during apoptosis and its inhibitor ICAD. Nature 391: 43-50, 1998. (Pubitemid 28079208)
48. Herzeg Z and Wang Z-Q: Function of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death. Mutation Res 477: 97-110, 2001.
49. Stuurman N, Heins S and Aebi U: Nuclear lamins: their structure, assembly, and interactions. J Struct Biol 122: 42-66, 1998. (Pubitemid 28411184)
50. Rao L, Perez D and White E: Lamin proteolysis facilitates nuclear events during apoptosis. J Cell Biol 135: 1441-1455, 1996. (Pubitemid 26427643)
51. Buenida B, Santa-Maria A and Courvalin JC: Caspase-dependent proteolysis of integral and peripheral proteins of nuclear membranes and nuclear pore complex proteins during apoptosis. J Cell Sci 112: 1743-1753, 1999. (Pubitemid 29295050)
52. Oltvai Z and Korsmayer S: Bcl-2 heterodimerizes in vivo with conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609-619, 1993. (Pubitemid 23259742)
53. Pepper C, Hoy T and Bentley DP: Bcl-2/Bax ratios in chronic lymphocytic leukemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer 76: 935-958, 1997.
54. Genini D, Adachi S, Chao Q, et al: Deoxyadenosine analogs induced programmed cell death in chronic lymphocytic leukemia by damaging the DNA and by directly affecting the mitochondria. Blood 96: 3537-3543, 2002.
55. Marzo J, Perez-Galan P, Giraldo P, Rubio-Felix D, Anel A and Naval J: Cladribine induces apoptosis in human leukaemia cells by caspase-dependent and -independent pathways acting on mitochondria. Biochem J 359: 537-546, 2001. (Pubitemid 33063377)